Contemplated compositions and methods are drawn to biomarkers and methods related to treatment of neoplastic disease with Hec1 inhibitor. Gene status and/or expression levels of Hec1 (HEC), Rb (RB1), and/or p53 (TP53) may be useful as biomarkers for sensitivity to treatment with a Hec1 inhibitor. In addition, Hec1 inhibitors may show synergistic effects when used in conjunction with cytotoxic drug.所使用之組合物和方法係作為與Hec1抑制劑一起治療腫瘤疾病相關的生物標誌物和方法。Hec1(HEC)、Rb(RB1)及/或p53(TP53)之基因狀態及/或表現量可作為對Hec1抑制劑治療之敏感性的生物標記。此外,Hec1抑制劑與細胞毒性藥物結合使用時,能表現出協同效應。